Trials / Completed
CompletedNCT00035100
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian, or peritoneal cancers. Recruitment in the United States is complete but the study is still enrolling in other countries.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | epothilone b |
Timeline
- Start date
- 2001-09-01
- Primary completion
- 2003-06-01
- First posted
- 2002-05-03
- Last updated
- 2012-04-16
Locations
8 sites across 5 countries: United States, Canada, Netherlands, Slovakia, United Kingdom
Source: ClinicalTrials.gov record NCT00035100. Inclusion in this directory is not an endorsement.